Ngl Fine Chem Ltd

Ngl Fine Chem Ltd maintains a relatively strong liquidity position, with a current ratio of 2.46, indicating that the company has more than twice as many current assets as current liabilities. However, the company's cash and equivalents amount to INR 13.25 million, which is significantly lower than its long-term debt of INR 324.42 million, resulting in a net cash position that is negative after subtracting total debt. This suggests that the company may need to rely on operating cash flow or external financing to meet long-term obligations.

In terms of profitability, the company's return on equity (ROE) is 4.68%, and its return on assets (ROA) is 3.46%. These figures are below the industry median for pharmaceutical companies, which typically report ROE and ROA in the range of 8-12% and 5-8%, respectively. The company's operating margin is 12.63% (calculated as operating income of INR 125.63 million divided by revenue of INR 994.62 million), which is also below the industry median of 15-18%. This suggests that the company is underperforming in terms of profitability relative to its peers.

The company's revenue is concentrated in a single geographic market, India, which accounts for the majority of its sales. There is no indication of significant international operations or diversification in the financial data provided. This concentration increases the company's exposure to local economic and regulatory risks, such as changes in pricing regulations or healthcare policy in India.

Looking at the company's growth trajectory, the outlook for the current fiscal year is modest, with revenue expected to remain relatively flat. The company's capital expenditures are negative (INR -285.24 million), indicating that it is generating more cash from operations than it is investing in new assets. This could suggest a conservative approach to growth or a focus on debt reduction. However, the lack of significant investment may limit the company's ability to expand its product portfolio or enter new markets in the long term.

The company's risk profile is characterized by medium liquidity risk and low dilution risk. The liquidity risk is primarily due to the negative net cash position after accounting for long-term debt. The dilution risk is low, as the number of shares outstanding has not changed between the basic and diluted counts, indicating no imminent threat of share dilution from stock options or convertible securities. However, the company's reliance on operating cash flow to service its debt may increase its vulnerability to economic downturns or disruptions in its supply chain.

There are no recent events or filings that indicate significant changes in the company's operations or financial position. The company's latest financial report does not mention any major acquisitions, divestitures, or strategic partnerships that would impact its future performance. The absence of such events suggests a stable but potentially stagnant business model.

Debt-to-equity ratio of 0.12 is lower than the cohort median of 0.18, reflecting a conservative leverage profile.

Revenue grew 16% year-over-year to INR 3.68 billion, showing top-line expansion despite margin pressures.

Long-term debt surged to INR 771 million, more than doubling from INR 300 million in the prior period.

Revenue INR 3.39B, +21,8% YoY; Operating income +80,8% YoY.

• ▍Revenue INR 3.39B, +21,8% YoY
• ▍Operating income +80,8% YoY
• ▍Net income +101,6% YoY
• ▍Free cash flow +3 433,8% YoY
• ▍Net margin 12.2%

Revenue INR 2.78B, −12,4% YoY; Operating income −59,9% YoY.

• ▍Revenue INR 2.78B, −12,4% YoY
• ▍Operating income −59,9% YoY
• ▍Net income −58,9% YoY
• ▍Free cash flow −124,9% YoY
• ▍Net margin 7.4%